The good results of the international ProDERM trial, evaluating Octagam® intravenous immunoglobulin versus placebo in 95 adults with dermatomyositis, led to an extension of the indication in 2022. Post-hoc analysis of these data shows that monthly infusions of Octagam® :
- a significant improvement versus placebo in the cutaneous manifestations of the disease (CDASI-A and CDASI-D indexes), regardless of their initial severity,
- a reduction of at least 35% in the CDASI-A score in more than 70% of participants by week 28, a threshold associated with a significant change in quality of life.
